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A 25 year old man with a history of UC was admitted in our hospital 
for the occurence of bloody diarrhea. Blood exams showed normal 
ALT (32 U/L) and AST (27 U/L), and increased ERS (45 mm). 
Abdominal ultrasound where performed with no evidence of liver 
diseases. Colonoscopy showed left colitis consistent with UC 
exacerbation. He started 40 mg/day of methylprednisolone therapy 
with improvement of his symptoms.  Therapy was tapered to 16 mg in 
4 weeks. After 40 days he performed blood exames and a raise of 
ALT value to 106 was observed. AST remained normal (41 U/L). An 
abdominal ultrasound examination was repeated with the evidence of 
fat infiltration consistent with liver steatosis. Hepatitis virus (HAV, 
HBV, HCV, CMV and EBV) and antibodies against mitochondria, 
smooth muscle and nuclear antigens were not detected by serological 
tests performed. Liver biopsy showed macrovescicular hepatocellular 
fat accumulation, periportal inflammation and mild fibrosis. The 
patient denied a history of alcohol abuse and a diagnosis of 
nonalcoholic steatohepatitis was made. He stopped the steroid 
treatment in two weeks and ALT value gradually decrease to 
normality. After six months abdominal ultrasound showed a normal 
liver. Steatohepatitis appears after a short course of steroid for 
ulcerative colitis. Although drug discontinuation seems effective to 
induce remission of this condition a careful follow up of patients 
submitted to steroids has to be performed for the possibility to 
develop liver failure. 
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Background and aim: non-alcoholic steatohepatitis (NASH)  is a 
chronic liver disease that can run its course towards cirrhosis. 
Genetic and metabolic factors, largely unknown, are likely involved 
in its pathogenesis. Some authors hypothesised that the Helicobacter 
Pylori (HP) might promote progressive liver disease by inducing 
pro-inflammatory cytokines production in the portal system. The 
seroprevalence of  HP infection in subjects with NASH is presently 
unknown. Aim of our study was to evaluate the prevalence of H. 
pylori infection and of more virulent strains in patients with NASH. 
Material and Methods: Thirteen consecutive male patients, aged 
35.6±7.5 yr (mean±SD), with a clinical and histological diagnosis of 
NASH, were studied. The control group consisted of 13 male blood 
donors, matched for age (mean 34.8±3.6 years), resident in the same 
area and  comparable for socio-economic status. Patients and 
controls were tested for serum IgG against H. pylori and the CagA 
antigen (ELISA Helori-test® Eurospital, Trieste, Italy). Results:
Antibodies against H.pylori were present in 3/13 (23%) patients and 
4/13 (31%) blood donors (p= n.s.). The anti-CagA antibodies were 
detected in 3/3 (100% of  infected patients, 23% of all cases) patients 
compared to 1/4 (25% of infected controls, 7,7% of all controls) in 
the blood donors. Conclusions: the prevalence of H. pylori infection 
in NASH group and in controls was similar in our study. However, 
the impressive prevalence of more virulent strains in patients with 
NASH  needs to be further investigated. 
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Aim: To retrospectively compare the efficacy, the tolerability, in terms 
of discontinuation of therapy (DT), and the predictor factors of therapy 
success of three regimens of treatment for chronic hepatitis C, in current 
clinical practice. End points considered were: 1) SVR: sustained viral 
responses; 2) R: relapse; 3) NR: Nonresponse; 4) DT 
Patients and methods: We retrospectively analyzed the data of 164 
consecutive naive patients treated from 1992 to 2001. Group A: 109 pts 
received recombinant alpha Interferon 6MU Tiw for 12-16 weeks 
followed by 3MU Tiw, over a period of 48 weeks. Group B: 28 pts 
received recombinant alpha Interferon 6 MU Tiw for 12-16 weeks 
followed by 3MU Tiw , plus 1000-1200 mg Ribavirin over a period of 
24 (genotype 2-3) or 48 weeks; Group C: 27 patients received Peg-
Interferon alpha-2b 80 mcg Ow (27 pts) , plus 1000-1200 mg Ribavirin 
over a period of 24 (genotype 2-3) or 48 weeks. 
Results:  The characteristic of patients in the treatment groups were 
similar (age, sex, duration of infection, HCV genotype, histologic stage 




IFN + RBV 
(group B) 
PEG-IFN + RBV  
(Group C) 
 N=109 N= 28 N=27  
DT 13 (12%) 2 (7%) 5 (19%) 
NR 46 (48%) 10 (38%) 6 (27%) 
R 29 (30%) 6 (24%) 3 (14%) 
SVR 21(22%) 10 (38%) 13 (59%) 
Conclusions: According to the clinical trials, our results confirm in 
clinical practice that: significantly more patients treated with PEG-
Interferon alpha plus ribavirin had a SVR than those treated with 
Interferon alone (59%vs22%, p=0,002) or Interferon plus ribavirin 
(59% vs 38%, p<0,05). The tolerability was similar in the three groups. 
In univariate analyses, predictors of SVR were: low levels of  GGT, 
ALP, TGL (p<0,05); HCV genotype non-1 (p<0,005); stage 1 at biopsy 
(p<0,001).
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Aims: The tolerability profile of PEG-IFN α2b is similar to the one of 
IFN α2b in patients (pz.) with chronic hepatitis C. We have considered 
the safety profile of PEG-IFN α2b+Ribavirin compared with the one 
of Interferon α2b+Ribavirin in the treatment of chronic hepatitis C. 
Methods: 43 patients have been treated with PEG-IFN α2b at the dose 
of 1 µg/kg weekly+Ribavirin 1-1,2 g/die (Group A) and compared 
with 40 patients previously treated with IFN α2b 3 MU/ 3 times 
weekly +Ribavirin at the same dosage (Group B). Contraindications 
for interferon therapy have been excluded. 
Results: In Group A 7 patients (16.3%) have discontinued the therapy, 
6 for adverse events and 1 for severe neutropenia; in group B only 2 
(5%) patients have interrupted the therapy for side effects 
(depression). A dose modification has been required in 7 pz (16.3%) 
for neutropenia in group A compared with 2 (5%) pz of group B; 11 pz 
(25,6%) for anaemia in group A against 5 pz. (12.5%) of group B; 4 pz 
(9%) for thrombocytopenia opposite to 2 (5%) in Group B. The 
frequency of flu-like syndrome has been similar in the two groups 
(40%vs 35%). 
In Group A, 6 cases of thyroid dysfunction have been shown (1 
hyperthyroidism, which has required therapy discontinuation and 5 
hypothyroidism, with a consequent substitutive hormonal therapy), a 
young man has presented a severe arrhythmias (FA which required 
electrical cardioversion), 2 patients have developed severe depression, 
which has caused interruption of therapy, 5 patients have instead 
developed mild–moderate depression, which has not determined a 
discontinuation of the therapy. In Group B we have found 2 cases of 
asymptomatic hypothyroidism and no hyperthyroidism; 2 patients 
have shown severe depression, with consequent dose discontinuation; 
none has had cardiac syndrome. 
Conclusion: In our experience PEG-IFN has been associated with a 
higher frequency of rare and severe side effects or laboratory 
abnormalities compared with IFN α2b.
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